EUVIMEDEUVIMED entdecken
Crossref

UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-Activated Protein Kinase-Mediated Induction of Mitophagy

Zhiqiang Zhuang, Yuxi Zhu, Jun Tao, Yandong Liu, Jie Lin, Chunjie Yang, Chule Dong, Xing Qin, Qun Li, Russel J Reiter, Guizhen Wang, Zhaohui Pei und 1 weitere

Pharmacology · 2024

DOI: 10.1159/000541569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology, 2024. Verfasst von Zhiqiang Zhuang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Mitophagy, Diabetes Mellitus, Experimental, AMP-Activated Protein Kinases, Diabetic Cardiomyopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetes mellitus is known to provoke devastating anomalies in myocardial structure and function, while effective therapeutic regimen is still lacking. The selective protease inhibitor UCF101 (5-[5-(2-nitrophenyl) furfuryl iodine]-1,3-diphenyl-2-thiobarbituric acid) has been shown to fend off ischemic heart injury, although its impact on diabetic cardiomyopathy remains elusive.

Methods

Our present work was conducted to examine the effect of UCF101 on experimental diabetes-evoked cardiac geometric and functional abnormalities as well as mechanisms involved. Adult mice were made diabetic using streptozotocin (STZ, 50 mg/kg, i.p., for 5 days) while receiving UCF101 (7.15 mg/kg, i.p.).

Results

STZ evoked cardiac hypertrophy, interstitial fibrosis, mitochondrial ultrastructural damage, oxidative stress, dampened autophagy (LC3B, Beclin 1, elevated p62), mitophagy (FUNDC1 and Parkin with upregulated TOM20), increased left ventricular end systolic diameter, reduced fractional shortening, ejection fraction, cardiomyocyte shortening capacity, velocities of shortening/re-lengthening, and rise in intracellular Ca2+ in conjunction with elongated diastole and intracellular Ca2+ removal, the responses were overtly reconciled by UCF101 with little effects from UCF101 itself. Levels of cell injury markers Omi/HtrA2, TNFα, and stress signaling (JNK, ERK, p38) were overtly enhanced along with compromised phosphorylation of cellular fuel AMP-activated protein kinase (AMPK) (Thr172) and cell survival molecule GSK3β, as well as downregulated SERCA2a and elevated phospholamban, the effect was reversed by UCF101 (except for SERCA2a). AMPK knockout, pharmacological inhibition, the mitophagy inhibitor liensinine, and parkin knockout nullified UCF101-offered cardioprotection in diabetes. UCF101 reversed STZ-induced upregulation in the AMPK degrading enzymes PP2A and PP2C.

Conclusion

These findings suggest that UCF101 rescues diabetes-mediated alterations in cardiac structure and function, likely through AMPK-mediated regulation of mitophagy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitophagyDiabetes Mellitus, ExperimentalAMP-Activated Protein KinasesDiabetic CardiomyopathiesVentricular RemodelingCardiotonic AgentsAnimalsMaleMiceMice, Inbred C57BLMyocardial ContractionMyocytes, CardiacOxidative Stress

Stichwörter der Autor:innen

AMP-activated protein kinaseContractile functionDiabetesHeartMitophagyUCF101

Substanzen

AMP-Activated Protein KinasesCardiotonic Agents

Autor:innen und Institutionen

  • Department of Rehabilitation Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • The Second Department of Cardiology, Nanchang City Renmin Hospital, Nanchang, China.
  • Department of Cardiovascular Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China.
  • National Clinical Research Center for Interventional Medicine, Shanghai, China.
  • Shanghai Institute for Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China.

Zitieren

APA

Zhuang, Z., Zhu, Y., Tao, J., Liu, Y., Lin, J., Yang, C., Dong, C., Qin, X., Li, Q., Reiter, R. J., Wang, G., Pei, Z., & Ren, J. (2024). UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-Activated Protein Kinase-Mediated Induction of Mitophagy. Pharmacology. https://doi.org/10.1159/000541569

Vancouver

Zhuang Z, Zhu Y, Tao J, Liu Y, Lin J, Yang C, et al. UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-Activated Protein Kinase-Mediated Induction of Mitophagy. Pharmacology. 2024. doi:10.1159/000541569

BibTeX
@article{Zhuang2024,
  author = {Zhuang, Zhiqiang and Zhu, Yuxi and Tao, Jun and Liu, Yandong and Lin, Jie and Yang, Chunjie and Dong, Chule and Qin, Xing and Li, Qun and Reiter, Russel J and Wang, Guizhen and Pei, Zhaohui and Ren, Jun},
  title = {UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMP-Activated Protein Kinase-Mediated Induction of Mitophagy},
  journal = {Pharmacology},
  year = {2024},
  doi = {10.1159/000541569}
}
Kostenlos starten →